Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages 1020-1031

  Bolinder, Jan ^a   Ljunggren, Östen ^b   Kullberg, Joel ^b   Johansson, Lars ^b,c   Wilding, John ^c   Langkilde, Anna Maria ^d   Sugg, Jennifer ^e   Parikh, Shamik ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DAPAGLIFLOZIN; DIURETIC AGENT; HEMOGLOBIN A1C; LIPID; METFORMIN; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BALANITIS; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY FLUID; BODY MASS; BODY WEIGHT; CANDIDURIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; DEHYDRATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSURIA; EDEMA; ESOPHAGUS HEMORRHAGE; FEMALE; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART RATE; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INTRAABDOMINAL FAT; KERATITIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPONDYLOSIS; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VAGINAL PRURITUS; VERTIGO; VULVOVAGINITIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; AGED; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 84858020943     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2260     Document Type: Article

References (37)

1. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D 2008 Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 10(Suppl 1):8-15
2. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S 2005 Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 70:90-97 (Pubitemid 41207652)
3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB 2008 Is glycemic control improving in U.S. adults? Diabetes Care 31:81-86
4. Liebl A, Mata M, Eschwège E 2002 Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 45:S23-S28 (Pubitemid 34762211)
5. Tang L, Chen X, Chen H, Zhao L, Hu S 2003 The financing burden of treatment of diabetes-II and its symptom in urban China. Chin Health Econ 12:21-23
6. Defronzo RA 2009 Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795
7. Wright EM, Hirayama BA, Loo DF 2007 Active sugar transport in health and disease. J Intern Med 261:32-43 (Pubitemid 46046470)
8. +/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14-C21
9. Nair S, Wilding JP 2010 Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95:34-42
10. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN 2008 Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149 (Pubitemid 351480378)
11. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF 2010 Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217-2224
12. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-2233
13. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S 2011 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928-938
14. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT 2009 A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:1656-1662
15. Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
16. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ 2009 Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163-1172
17. Albanese CV, Diessel E, Genant HK 2003 Clinical applications of body composition measurements using DXA. J Clin Densitom 6:75-85 (Pubitemid 36693801)
18. Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G 2009 Body composition assessment by dual-energy x-ray absorptiometry (DXA). Radiol Med 114:286-300
19. Kullberg J, Ortiz-Nieto F, Johansson L 2009 Reproducibility of hepatic triglyceride content assessment in normals using localized magnetic resonance spectroscopy. Diabetes Obes Metab 11:516-518
20. Hochberg Y 1988 A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802
21. Zhang M, Tsiatis AA, Davidian M 2008 Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 64:707-715
22. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, Li T, LaCreta FP, Boulton DW 2011 Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13:47-54
23. National Research Council 2010 The prevention and treatment of missing data in clinical trials. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics (CNSTAT), Division of Behavioral and Social Sciences and Education. Washington, DC: National Academies Press
24. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Serdula M, Brown TJ, Schmid CH, Lau J 2004 Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 117:762-774 (Pubitemid 39482530)
25. Freemantle N, Holmes J, Hockey A, Kumar S 2008 How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 62:1391-1396
26. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA 2007 Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496-506 (Pubitemid 47187337)
27. Grundy SM 2008 Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28:629-636.
28. de Koning L, Merchant AT, Pogue J, Anand SS 2007 Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 28:850-856
29. Bays HE 2011 Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 57:2461-2473
30. Hermansen K, Mortensen LS 2007 Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 30:1127-1142 (Pubitemid 350172854)
31. Wilding JP, Hardy K 2011 Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 342:d410
32. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA 2006 Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29:510-514 (Pubitemid 44115345)
33. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM 2002 Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res [Erratum (2002) 10:following table of contents] 10:1008-1015
34. Smith SR, DeJonge L, Volaufova J, Li Y, Xie H, Bray GA 2005 Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54:24-32 (Pubitemid 39572453)
35. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U 2010 Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33:1734-1737
36. Gallwitz B, Haupt A, Kraus P, Peters N, Petto H, Dotta F, Petto H, Poll L, Rose L, Schernthaner G 2010 Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. Diabetes Obes Metab 12:1127-1128
37. Harder H, Nielsen L, Tu DT, Astrup A 2004 The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27:1915-1921 (Pubitemid 38989232)